Bioinformatics and Multiepitope DNA Immunization to Design Rational Snake Antivenom by Wagstaff, Simon C et al.
Bioinformatics and Multiepitope DNA
Immunization to Design Rational Snake
Antivenom
Simon C. Wagstaff
*, Gavin D. Laing, R. David G. Theakston, Christina Papaspyridis, Robert A. Harrison
Alistair Reid Venom Research Unit, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, United Kingdom
Funding: Funding for this work was
provided by a Wellcome Trust
project grant to SCW and RAH
(072426).
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Ken Winkel,
University of Melbourne, Australia
Citation: Wagstaff SC, Laing GD,
Theakston RDG, Papaspyridis C,
Harrison RA (2006) Bioinformatics
and multiepitope DNA
immunization to design rational
snake antivenom. PLoS Med 3(6):
e184. DOI: 10.1371/journal.pmed.
0030184
Received: November 23, 2005
Accepted: January 31, 2006
Published: June 6, 2006
DOI:
10.1371/journal.pmed.0030184
Copyright:  2006 Wagstaff et al.
This is an open-access article
distributed under the terms of the
Creative Commons Attribution
License, which permits unrestricted
use, distribution, and reproduction
in any medium, provided the
original author and source are
credited.
Abbreviations: db, database; DC,
disintegrin; EoVgDbEST, E. ocellatus
venom gland EST database; EST,
expressed sequence tag; MAP,
multiple antigenic peptide; MP,
metalloproteinase; SVMP, snake
venom metalloproteinase; VgDbEST,
venom gland EST database
*T ow h o mc o r r e s p o n d e n c es h o u l db e
addressed. E-mail: simonw@liv.ac.uk
ABSTRACT
Background
Snake venom is a potentially lethal and complex mixture of hundreds of functionally diverse
proteins that are difficult to purify and hence difficult to characterize. These difficulties have
inhibited the development of toxin-targeted therapy, and conventional antivenom is still
generated from the sera of horses or sheep immunized with whole venom. Although life-
saving, antivenoms contain an immunoglobulin pool of unknown antigen specificity and
known redundancy, which necessitates the delivery of large volumes of heterologous
immunoglobulin to the envenomed victim, thus increasing the risk of anaphylactoid and serum
sickness adverse effects. Here we exploit recent molecular sequence analysis and DNA
immunization tools to design more rational toxin-targeted antivenom.
Methods and Findings
We developed a novel bioinformatic strategy that identified sequences encoding
immunogenic and structurally significant epitopes from an expressed sequence tag database
of a venom gland cDNA library of Echis ocellatus, the most medically important viper in Africa.
Focusing upon snake venom metalloproteinases (SVMPs) that are responsible for the severe
and frequently lethal hemorrhage in envenomed victims, we identified seven epitopes that we
predicted would be represented in all isomers of this multimeric toxin and that we engineered
into a single synthetic multiepitope DNA immunogen (epitope string). We compared the
specificity and toxin-neutralizing efficacy of antiserum raised against the string to antisera
raised against a single SVMP toxin (or domains) or antiserum raised by conventional (whole
venom) immunization protocols. The SVMP string antiserum, as predicted in silico, contained
antibody specificities to numerous SVMPs in E. ocellatus venom and venoms of several other
African vipers. More significantly, the antiserum cross-specifically neutralized hemorrhage
induced by E. ocellatus and Cerastes cerastes cerastes venoms.
Conclusions
These data provide valuable sequence and structure/function information of viper venom
hemorrhagins but, more importantly, a new opportunity to design toxin-specific antivenoms—
the first major conceptual change in antivenom design after more than a century of
production. Furthermore, this approach may be adapted to immunotherapy design in other
cases where targets are numerous, diverse, and poorly characterized such as those generated
by hypermutation or antigenic variation.
The Editors’ Summary of this article follows the references.
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Random sequencing of expressed genes (ESTs) often
provides a rapid and affordable opportunity to gain a
comprehensive insight into the biochemical complexities
underlying many biological processes. Identifying the most
clinically important toxins in venoms to inform the immuno-
therapeutic treatment of snake bite exempliﬁes this approach.
Snake venom typically contains over 100 inter- and intra-
speciﬁcally diverse proteins of varying toxicity that are
difﬁcult to purify in sufﬁcient amounts for immunization
and are often very poorly characterized at the protein
sequence and functional levels. Whilst the increasing volume
of genomic and transcriptomic data are undoubtedly beneﬁ-
cial here, our current ability to bioinformatically transform
these data into novel therapies [1] is not well developed.
Conventional snake antivenom remains the only effective
treatment of snake envenoming, but because of the above
problems,currentimmunizationprotocolsmakenoattemptto
target the immune responses to the most clinically important
toxins, but involve hyperimmunization of horses or sheep with
whole venom. Variation in representation, immunogenicity,
and toxicity of venom proteins means that (i) not all conven-
tional antivenoms contain antibodies to important toxins [2],
and (ii) dose-efﬁcacy is reduced by antibodies to nontoxic
components [3,4]. This necessitates the administration of large
volumes (30 to . 300 ml at 80 mg protein/ml) of antivenoms
that increase the risk of early anaphylactoid and late serum
sickness adverse reactions [5]. A systematic approach to select
immunoprotective sequences for immunization using molec-
ular sequence data alone would generate novel polyspeciﬁc
antivenoms of high avidity, thus increasing dose efﬁcacy and
reducing toxicity to envenomed victims.
DNA immunization offers a rational approach to the
design of toxin-speciﬁc immunotherapy, which we have
previously demonstrated to induce titres and protective
responses appropriate for antivenom production [6,7] and
generate antisera cross-reactive with venoms from phyloge-
netically distinct viper species and genera [8]. In light of the
above and the sequence conservation of venom toxins, we
proposed that a systematic approach to identifying common
antigenic epitopes of venom toxins from venom gland EST
databases would provide a rational approach to generating
interspeciﬁc or intergeneric protective antibody responses
satisfying the most desirable polyspeciﬁc properties of an
antivenom.
As proof of principle, a comprehensive EST survey from
the venom glands of E. ocellatus, the most medically important
snake in West Africa, was undertaken and combined with a
bioinformatic approach to identify epitopes of key structural
or functional signiﬁcance. We focused upon the group of
snake venom metalloproteinases (SVMPs) responsible for the
main, frequently lethal hemorrhagic effect of viper envenom-
ing [9]. SVMPs are complex targets due to their multifunc-
tional, multidomain nature and broad substrate speciﬁcity.
SVMPs transcripts are classiﬁed by precursors encoding the
metalloproteinase domain alone (class PI), metalloproteinase
and C-terminal disintegrin domain (class PII), or disintegrin-
like and cysteine-rich domains (class PIII) [10,11]. Additional
and extensive post-translational diversity of PII and PIII
SVMPs also provide a reservoir in whole venom for a diverse
array of processed disintegrins that interfere with normal
mechanisms of tissue repair and hemostasis [12,13]. Although
their principal effect is the disruption of microvessel
architecture by degradation of basement membrane compo-
nents [14], this diversity endows SVMPs with a multiplicity of
functions that are difﬁcult to predict from transcriptional
data alone. These functions include exacerbation of systemic
bleeding by ﬁbrinolytic activities, cleavage (and thus con-
sumption) of coagulation factors, and disruption of platelet
aggregation resulting in a variety of tissue-disruptive [14],
coagulopathic, and haemostasis-disruptive mechanisms [15–
19] that contribute to the overall hemorrhagic pathology.
Despite determination of the solution structures of several PI
and PII SVMPs, the lack of structural information for PIII
SVMPs leaves many questions concerning the structure/
function relationships unanswered, particularly mechanisms
of dimerization [20,21] and their covalent addition to a C-
type lectin domains generating the PIV isoforms [22,23].
Here we describe for the ﬁrst time (i) the design of a
synthetic DNA immunization construct (EoSVMP string)
containing a string of SVMP epitopes represented across
numerous and diverse SVMP isoforms, (ii) the cross-generic
and cross-speciﬁc antibody responses to multiple SVMPs
induced by the EoSVMP string DNA immunogen, and (iii) the
in vivo neutralization of venom-induced hemorrhage by the
anti-EoSVMP string antibody.
Methods
Specimens and Venom
Venom glands were dissected from ten wild-caught adult
specimens of E. ocellatus (Kaltungo, Nigeria) of random sizes
(i.e., ages) and gender 3 d after venom extraction, when
transcription is maximal [24]. Venom for immunoblotting
was provided from pooled lyophilized venom extracted from
wild-caught E. ocellatus (Kaltungo, Nigeria), C. cerastes (Egypt),
Bitis arietans (Ghana), and B. gabonica (Ghana) snakes main-
tained in the herpetarium of the Liverpool School of Tropical
Medicine.
cDNA Library Synthesis and Sequencing
Pooled venom glands were snap frozen then homogenized
under liquid nitrogen, and total RNA was extracted using
TriReagent (Sigma, Poole, United Kingdom). mRNA was
puriﬁed using oligo-dt cellulose chromatography (Amersham,
Buckinghamshire, United Kingdom). Ten micrograms of
mRNA was used to construct a directional plasmid cDNA
library of 1.4 3 10
6 cfu/ml in Gateway CloneMiner (Invitro-
gen, Paisley, United Kingdom) using the ﬁrst 480 ng of eluted
cDNA from Sephacryl S-500 HR. Plasmid DNA isolated from
1,000 random colonies was sequenced (Lark Technologies,
Essex, United Kingdom) using M13 forward primers. Full
length sequencing of selected clones was achieved by single-
stranded primer walking with custom forward and anchored
oligo-dt reverse primers. These sequence data have been
submitted to the EMBL database (see ‘‘Accession Numbers’’
below).
Bioinformatics
Partial genome construction was undertaken on an Intel,
Dual 2.8GHz RedHat Enterprise Linux 9.0 workstation
running Biolinux 3.0 (available at: http://envgen.nox.ac.uk).
Sequence chromatograms were processed using Trace2dbest
PLoS Medicine | www.plosmedicine.org June 2006 | Volume 3 | Issue 6 | e184 0833
Rational Design of Antivenom(J. Parkinson, unpublished software) according to default
parameters except polyAþ removal, which was set to 15.
Clustering, assembly, and databasing of 1,000 sequences (100
sequences/round) was achieved by PartiGene [25] using
CLOBB1 perl script [26] modiﬁed at source code to apply
increased stringencies to initial pairwise comparisons of
100% over 50 bp. BLASTN/BLASTX annotation was achieved
against databases of Uniprot, TREMBL, and all Serpentes
sequences including ESTs and forward translations (mini-
mum ORF of 200 nt) generated using GETORF within
Jemboss [27]. Sequences were analyzed using CLUSTALX
and Jameson-Wolf [28] (DNASTAR, Madison, Wisconsin,
United States). In the absence of complete crystallographic
data from class PIII SVMPs, surface exposure was conﬁrmed
by overlay using CD-search [29] on available models of class I
Trimestatin [30] and the disintegrin Echistatin [31] (unpub-
lished data). Peptide composition was reﬁned using database
2 (db-2) (unpublished data).
De Novo Gene Synthesis of Epitope Strings for DNA
Immunization
Seven peptides were subjected to in silico concatenation
(each peptide separated by two lysine spacers), reverse
translation, murine codon optimization (available at: http://
www.codon.jp), and fragmentation into thermodynamically
balanced PCR primers for gene assembly using DNAWorks
[32]. PCR gene assembly was performed according to
previously described protocols [33] and recombination
cloning into Gateway Multisite (Invitrogen) facilitated by
the incorporation BP clonase recombination sites on the
outermost assembly primers. Correct inserts, veriﬁed by
sequencing, were subcloned upstream of an Igj leader
sequence in the DNA immunization plasmid pVaxSec,
creating the construct hereafter referred to as EoSVMP
string. The pVaxSec plasmid is a hybrid (unpublished data)
we generated from a vaccine-appropriate kanamycin-select-
able 3.0 Kb plasmid (pVax, Invitrogen) that lacked consensus
Kozak, ATG start, and signal peptide domains. The latter
were excised (NheI/HindIII) as a single sequence from an
ampicillin-selectable, 5.2 Kb plasmid, pSecTag (Invitrogen)
that we used in earlier studies [6].
Preparation of Immunogens for GeneGun DNA and MAP
Immunizations
To provide comparative immunological data to the sera
raised by immunization with the EoSVMP-string DNA
construct, mice were also immunized with DNA encoding
the metalloproteinase (MP) domain (Figure S1, 194–398),
disintegrin (DC) domain (399–616), and metalloproteinase
and disintegrin domains (MPDC) (194–616) of EOC00024
(EST: Eo_venom_05F04). Sequences were ampliﬁed by PCR
with complementary 59 and 39 primers, and the amplicons
cloned into pCR2.1 TOPO (Invitrogen) followed by subclon-
ing into pVaxSec. Following sequence veriﬁcation, trans-
formed colonies were grown in 500 ml of LB medium, and
plasmid DNA puriﬁed using MegaPrep plasmid DNA puriﬁ-
cation kit (Qiagen, Crawley, United Kingdom). Puriﬁed
pVaxSec plasmid (vehicle control) and pVaxSec/MP, pVax-
Sec/DC, pVaxSec/MPDC, and pVaxSec/EoSVMP string were
precipitated onto 1.6-lm gold beads and coated on the inner
surface of half-inch lengths of plastic (Tefzel) tubing accord-
ing to the manufacturer’s protocol (Bio-Rad, Hercules,
California, United States). The quantity of DNA gold beads
was adjusted to provide individual tubing (shots) of 1 lg DNA/
0.5 mg Au. The abdomens of anaesthetized female BALB/c
mice (18–20 g) were shaved and each subjected to four
‘‘shots’’ expelled under a burst of helium gas at 350 psi into
the epidermal layer using the Helios GeneGun (Bio-Rad).
Groups of six mice were immunized with the four pVaxSec
constructs or vector alone on weeks 0, 2, 4, 8, and 12 and sera
examined after the ﬁnal immunization. Multiple antigenic
peptides (MAPs) for each epitope EoMPep 1–6 were
synthesized by University of Birmingham (United Kingdom).
Each MAP (100 lg resuspended in PBS), was homogenized in
an equal volume of Freund’s complete adjuvant (Sigma), and
25 ll injected into groups of female 18- to 20-g BALB/c mice
(n ¼ 3) at four subcutaneous sites. Mice were boosted with
MAPs without adjuvant on two subsequent occasions, 3 wk
apart. Antisera against whole venom was raised in rabbits
hyperimmunized with increasing doses of E. ocellatus whole
venom initially in Freund’s complete adjuvant over an
established time period.
Immunoblotting
Venom was separated by NUPAGE (Invitrogen) under
reduced (8 lg, 4%–12% gradient NUPAGE, MOPS buffer) or
nonreduced (10 lg, 12% NUPAGE, MES buffer) conditions.
Following electrophoretic separation, gels were electroblot-
ted onto 0.45 lm nitrocellulose (Bio-Rad) according to
manufacturer’s protocols. E. ocellatus venom (15 lg) in native
sample buffer (62 mM Tris-Cl [pH 6.8], 30% glycerol, and
0.005% w/v bromophenol blue) was separated by Ornstein-
Davis discontinuous native PAGE on 8% resolving gel (375
mM Tris-Cl [pH 8.8]) with a 4% stacking gel (125 mM Tris-Cl
[pH 6.8]) at 200 V for 35 min in 250 mM Tris-Cl [pH 8.3] with
100 mM glycine followed by electroblotting in the same
buffer to nitrocellulose at 100 V for 1 h using MiniProtean III
(Bio-Rad). Following transfer, molecular mass markers were
visualized by reversible staining with Ponceau S. Membranes
were blocked in 20% soya milk in TBST (10 mM Tris-Cl [pH
8.5], 150 mM NaCl, and 0.1% Tween-20) overnight, followed
by washes in TBST then incubation in test antisera at 1/200
dilution in 5% nonfat skimmed milk in TBST for 3 h at room
temperature. Membranes were washed in TBST then incu-
bated with a 1/1,000 dilution of HRP-conjugated goat anti-
mouse immunoglobulins (Dako Cytomation, Cambridgeshire,
United Kingdom) in TBST for 1 h at room temperature, then
washed in TBST and developed using DAB peroxidase.
ELISA
Maxisorp plates (96-well; NUNC, Denmark) were coated
with whole E. ocellatus venom (100 ng/well) overnight at 4 8Ci n
0.05 M NaHCO3. Plates were washed with TBST and blocked
for 1 h in 5% nonfat skimmed milk in TBST at room
temperature. Individual murine sera were diluted at 1/200
then serially 1/5 in 5% nonfat skimmed milk, applied to wells,
then incubated overnight at þ4 8C. Plates were washed in
TBST then incubated with a 1/1,000 dilution of HRP-
conjugated goat anti-mouse IgG (Nordic, Tillburg, Nether-
lands) in TBST for 2 h at room temperature. Following
washing in TBST, plates were developed using 0.02% 2,29-
azino-bis (Sigma) in phosphate-citrate buffer (pH 4.0)
containing 0.015% H2O2, and absorbance measured at 405
nm using a Dynex OpsysMR plate reader.
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The minimum hemorrhagic dose, deﬁned as the amount of
venom required to produce a 10-mm diameter hemorrhagic
lesion 24 h after intradermal injection [34], was determined
to be 10 and 8 lg/mouse for E. ocellatus and C. cerastes venom,
respectively. These assays were performed according to
WHO-approved protocols [4]. This amount of venom was
preincubated with equal volumes of PBS (control) or test
antisera for 30 min at 37 8C before intradermal injection into
the dorsal skin of 18- to 20-g male CD-1 strain mice (E.
ocellatus venom: PBS, n¼3; rabbit anti-E. ocellatus venom, n¼
3; DNA immunization constructs, n¼3; and C. cerastes venom:
PBS, n¼3; rabbit anti-E. ocellatus venom, n¼3; pVaxSec, n¼
4; EpiString, n¼3). Venom-induced hemorrhagic lesions that
appeared on the inner surface of the skin 24 h later were
coded and measured blind in two directions at right angles
using digital calipers and background illumination. Percent-
age inhibition was calculated as the mean area zone of
inhibition for experimental groups relative to vehicle
controls (pVaxSec or PBS). A two-tailed Student’s t-test was
used to calculate p-values, assuming equal variance between
two sample means. All animal experiments were performed
using Home Ofﬁce-approved protocols that have been
reviewed and approved by the University of Liverpool local
ethical review committee.
Results
The Bioinformatic Pipeline to Design Toxin-Neutralizing
Immunotherapy
The bioinformatic pipeline used for this project is
described in Figure 1. Venom gland sequence chromatograms
were processed and clustered using CLOBB1.pl [26] under
conditions optimized to discriminate between venom gland
EST isoforms. The ﬁrst database, db-1, was populated by
PartiGene [25] and contains a BLAST-annotated transcrip-
tome for toxin cataloguing and identiﬁcation. The composi-
tion of the entire annotated E. ocellatus transcriptome from
db-1 is provided as Figure S2; toxins represented 47% of
transcripts. Venom gland transcriptomes typically contain a
high proportion of transcripts with no signiﬁcant matches
due to under-representation of snake venom toxins in public
databases [35,36] and will contain additional uncharacterized
toxin components. Following extraction, antigenic proﬁling
and alignment of selected toxins, a second, custom-designed
data mining solution (db-2) scored epitopes for cross-
reactivity against all ESTs and identiﬁed small antigenic
peptides with broad predicted toxin-neutralizing potential.
Peptides were concatenated in silico, separated by lysine
spacers, and codon-optimized before de novo gene synthesis
to create DNA immunogens.
SVMPs Are Diverse and the Most Abundant Toxin Group
in the E. ocellatus Venom Gland Transcriptome
In order to obtain a global panorama of the toxin
composition of E. ocellatus venom, ESTs were separated into
toxin families according to their BLAST similarity against
Uniprot/TREMBL databases. SVMPs dominated the toxin-
encoding proﬁle (58%, 243 transcripts) relative to other toxin
groups (Figure 2A), encoding isoforms from all the three (PI-
PIII) major SVMP isoform classes [10,11]. The relative
expression levels indicate that this transcriptome is domi-
nated by PIII isoforms relative to PI- and PII-encoding
transcripts (Figure 2A). These clusters represent 88% of all
expressed SVMPs, the remainder present as single copies.
Because clustering of venom toxin isoforms is especially
vulnerable to chimeric assemblies, two random clones from
each pentapeptide SVMP cluster were sequenced. This
conﬁrmed accurate assembly and resulted in the character-
ization of 11 novel SVMP transcripts collectively accounting
for 72% of SVMPs. The number and diversity of PIII
isoforms, the most potent hemorrhagins [9], is notable and
consistent with the hemorrhagic pathology of victims bitten
by this viper [37,38]. Full-length comparative sequence
analysis of the PI–PIII EoSVMP isoforms (provided in Figure
S1) illustrates the high degree of sequence and domain
conservation that characterizes the viper venom hemorrha-
gins [10,39]. The molecular diversiﬁcation of the E. ocellatus
SVMPs far exceeds that reported in the venom glands of
other viper species [35,36,40]. Our cDNA library was inten-
Figure 1. The Bioinformatic Pipeline Used to Identify Immunogenic
Peptides
EST chromatograms (A) are trimmed for contaminating sequences by
trace2dbest, imported into PartiGene [25], clustered using CLOBB [26],
BLAST-annotated, and finally used to populate db-1. Toxins are extracted
and aligned using CLUSTALX (B) before (C) antigenic predictions by
Jameson-Wolf (C) and three-dimensional superposition using CD-search
(D). Peptide composition was refined against db-2 (E) before sequence
incorporation into synthetic codon optimized DNA constructs for
immunization (db, database).
DOI: 10.1371/journal.pmed.0030184.g001
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normalization to provide transcriptomic data that best
reﬂects venom composition, including important isoform-
distinct sequence differences and toxin expression bias. It is
therefore not clear whether this diversity is consistently
reﬂected in individuals or results from population variation
in venom composition reﬂecting differences in age (size),
diet, and availability of local prey [41,42].
EoSVMP String Construction
The diversiﬁcation described above indicated that neutral-
ization of the hemorrhagic activity of whole venom will
require antibodies targeting surface-available and antigenic
epitopes contained within most, if not all, the numerous and
diverse SVMP isoforms. Since only limited structural infor-
mation is available for SVMPs, we ﬁrst performed Jameson-
Wolf antigenic proﬁling of representatives from each isoform
class (PI–PIII). This analysis identiﬁed six domains (EoMP 1–6)
whose antigenic proﬁles are similarly conserved across
isoforms (Figure 2B). These antigenic domains aligned to
functionally signiﬁcant domains (Figure 2C) as follows: EoMP
1, the catalytic zinc-binding motif (identiﬁed as Zn in Figure
2C); EoMP 2, integrin-targeting tripeptide motifs containing
a5b1 RGD (I-Bi) [43]; EoMP 4, containing an a2b1 ECD motif
[44,45] substituted for DCD motifs in EOC00024 and 22 (also
I-Bi); and EoMP 5, which contains a2b1 integrin binding VKC-
like motifs in jararhagin-C (IBii) [46]. Two additional domains
of unascribed functions, EoMP 3, the GEECDC box upstream
of IB-i, and EoMP 6, a C-terminal region in the cysteine-rich
domain, were also selected on the basis of their unusually
high level of interspeciﬁc and intergeneric sequence con-
servation [8,39] and high potential immunogenicity.
Multiple sequence alignment of the antigenic domains
EoMP 1–6 from all the full-length SVMP isoforms charac-
terized from this cDNA library demonstrated extensive
Figure 2. Identification of Conserved Domains in Snake Venom Metalloproteinases
(A) Proportional representation of toxin-encoding transcripts. The proportional representation of SVMP clusters are expanded as a histogram and
classified as PI–PIII isoforms. Identifiers for each cluster are indicated in parentheses. Minor SVMPs denote transcripts represented as singletons or
smaller SVMP clusters (four ESTs or fewer) whose isoform class could not be reliably identified. BPP, bradykinin-potentiating peptides; CTL, C-type lectin;
LAO, L-amino oxidases; PLA2, group II phospholipase A2; SP, serine proteinases; SVMP, snake venom metalloproteinases; VEGF, vascular endothelial
growth factors.
(B) Comparative Jameson-Wolf antigenic profiling of representatives of the PI (EOC00028), PII (EOC00006), PIII ECD motif (EOC00063), and PIII DCD motif
(EOC00024). The propeptide domain, which is proteolytically released from the zymogen [9], is excluded. Antigenic domains that show the greatest
levels of sequence conservation are indicated below each transcript (MP 1–6).
(C) Sequence alignment of E. ocellatus venom gland SVMP isoforms. The alignments are truncated and separated into three SVMP functional domains
annotated with antigenic domains (EoMP 1–6) and motifs of functional or catalytic significance. Residues identical to ecarin (Epl–Eca [Q90495]) are
shown in black for comparison. Full-length alignments are provided in Figure S1. I-Bi, integrin-targeting tripeptide motifs; I-Bii a2b1 integrin-binding
VKC-like motifs in jararhagin-C [46]; Zn, catalytic zinc-binding motif.
DOI: 10.1371/journal.pmed.0030184.g002
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(Figure 2C). This suggested that immunization with antigenic
domains (EoMP 1–6) from a small number of SVMPs would be
unlikely to induce potent cross-reactive antibody responses
capable of neutralizing venom-induced hemorrhage. To
create an antiserum that would react with epitopes repre-
sentative of all the SVMP isoforms, an additional data-mining
solution, database db-2, was developed to select a single
epitope from each antigenic domain present in the maximum
number of SVMP isoforms. Db-2 was used to evaluate the
frequency of peptides in the E. ocellatus venom gland EST
database (EoVgDbEST) by taking EST expression bias
(numerical EST representation and cluster diversity) into
account by reporting (i) the number (and size) of clusters
matched to each candidate query peptide, and (ii) the total
number of individual ESTs matched to each peptide. Using
db-2, the length of each antigenic domain (EoMP 1–6) was
incrementally reduced and the peptide composition reﬁned
into seven peptides (EoMPep 1–6) that represented the
maximum number of matches to SVMP clusters and ESTs
(Figures 2A and 3A). It should be noted that because of the
sequence divergence within the centre of domain EoMP 3
(Figure 2C, residues 415–440), this domain was separated into
two overlapping peptides, EoMPep 3a and 3b, which together
scored higher, by db-2, than a single peptide spanning
domain EoMP 3.
EoMPep 1–6 were synthesized, by de novo gene synthesis,
as a murine codon-optimized, single, multi-epitope se-
quence (EoSVMP string) that was then inserted into the
DNA immunization plasmid pVaxSec. Two lysines were
Figure 3. The EoSVMP String
(A) Upper graphic: Jameson-Wolf antigenic profiling of the mature EoSVMP string synthetic DNA immunization construct. Lower chart: Target domains
for individual MP epitopes. Cluster matches against each peptide are shown. The number of ESTs in each cluster is indicated in parentheses. a2b1, a2b1
integrin-binding motif in Jararhagin-C; Cys-rich, C-terminal region of the cysteine-rich domain; Dis-like, disintegrin-like domain; ECD, ECD motif and
flanks; MP, metalloproteinase catalytic domain; RGD, RGD-containing PII and flanking sequences.
(B) Complete nucleotide and coding sequence of EoSVMP string. Sequence and locations of epitopes, separated by lysine spacers are indicated.
DOI: 10.1371/journal.pmed.0030184.g003
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(ii) as sites for intracellular proteolytic cleavage by the DNA-
transfected epidermal cell, thus promoting their antigen
presentation as single epitopes. Figure 3B shows the primary
sequence, high antigenic proﬁle and location of epitopes in
the EoSVMP string.
EoSVMP String Induces Antibody Responses to Multiple
SVMP Isoforms
To provide comparison between (i) this SVMP epitope-
string immunization and (ii) our earlier single SVMP-
immunization approaches to generate toxin speciﬁc and
venom neutralizing antibody [6], we also immunized mice
with pVaxSec constructs expressing the metalloproteinase
domain only (MP), the disintegrin domain only (DC), or
metalloproteinase and disintegrin domains (MPDC) of the
SVMP transcript, EOC00024. This EST contig was selected
as a PIII SVMP paradigm for this comparison due to its
highest representation (55 ESTs) over other clusters (Figure
2A) and its similarity with other PIII SVMPs in EoVgDbEST,
and would therefore be expected to provide immunological
cross-reactivity to many SVMP isoforms. Sera from mice
immunized with the constructs expressing the MP, DC, or
MPDC domains of EOC00024 (Figure 4), however, showed
restricted speciﬁcity to isoforms mainly in the 55- to 60-kDa
molecular mass range (Figure 4A) but high titres against
whole venom as determined by ELISA (Figure 4D). In
comparison, and according to bioinformatic predictions,
sera from mice immunized with the EoSVMP string showed
intense and, importantly, extensive immunoreactivity to
diverse SVMPs in wide molecular mass ranges of 50–70 kDa
and 20–30 kDa (Figure 4A). EoSVMP string antiserum,
however, showed a lower ELISA titre and less intense native
immunoblot reactivity to whole venom than EOC00024
antisera (Figure 4B and 4D) or rabbit anti-E. ocellatus venom
(Figure 4C), and it was only weakly reactive against the
venom of C. cerastes (Figure 4C). Whilst the intensity of
immunoreactivity is higher against reduced venom proteins
than native proteins, the multiplicity of venom components
reactive with the EoSVMP string antiserum was similar
(Figure 4A–4C). This suggests that the EoSVMP string
induces polyspeciﬁc antibody responses capable of binding
to both linear and native, conformationally intact SVMP
epitopes.
EoSVMP String Induces Cross-Generic and Cross-Specific
Antibody Responses
We interrogated other viper venom gland EST databases to
predict the extent to which epitopes (EoMPep 1–6) are
conserved in venoms of other medically important African
vipers. This analysis, with the exception of EoMPep 1 and 2,
predicted conservation of the majority of epitopes in C. cerastes
(Figure 5A), but only EoMPep 6 in the gaboon viper, Bitis
gabonica(Figure5B).Serafrommiceimmunizedwithindividual
MAPs of EoMPep 1–6 were used to conﬁrm these predictions.
All epitopes, except EoMPep 2 and 5, were detected with these
antisera in the venom of phylogenetically distinct vipers
distributed throughout Africa: E. ocellatus (West Africa) (Figure
5C),C.cerastes(NorthAfrica)(Figure5D),B.gabonica(Figure5E),
and the puff adder, B. arietans (pan-African distribution)
(Figure 5F). As predicted, EoMPep 1 was restricted to E.
ocellatus, whereas EoMPep 3a and EoMPep 3b were immuno-
logically conserved between E. ocellatus and C. cerastes; the latter
sera also reacted with components of B. arietans venom, but not
withthoseinthevenomoftherelatedspecies,B.gabonica.There
were notable differences in intensities; EoMPep 4 antiserum
was intensely reactive with venom components from E. ocellatus
andC.cerastesbutnotwithB.gabonicaandB.arietans,whereasthe
converse was true for EoMPep 6. Most signiﬁcantly, the
EoSVMP string antiserum consistently recognized more SVMP
isoforms in all venoms than antisera raised against single
epitopes. Taken together, these results indicate that the
EoSVMP string DNA immunogen induces antibody responses
to multiple conserved epitopes, but with intensities that vary
withexpressionlevelsorantigenicityofitsconstituentepitopes
in venoms of different vipers.
Figure 4. EoSVMP String Antiserum Recognizes Multiple SVMP Isoforms
(A and B) Comparative reactivity on immunoblots using pooled murine antisera raised against EOC00024 domains (MP, DC, and MPDC) and EoSVMP
string to E. ocellatus venom under reduced SDS-PAGE (A) and native PAGE (B) conditions.
(C) Comparative reactivity on native PAGE immunoblots of EoSVMP string antiserum to venoms from E. ocellatus (Eo), C. cerastes (Cc), B. arietans (Ba),
and B. gabonica (Bg). Cross-reactivity of rabbit antisera against E. ocellatus venom (anti-EoV) is shown for comparison.
(D) IgG ELISA end-point titres determined by serial dilution of murine antisera. Values represent the mean dilution (6 standard error of the mean) of
sera equaling the titre of sera from unimmunized BALB/c mice.
DOI: 10.1371/journal.pmed.0030184.g004
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Hemorrhagins
The EoMpep 4 (SECD motif) is highly conserved in PIII
hemorrhagins, whose extensive level of sequence homology
and domain structure would be expected to produce com-
parablemobilitiesonWesternblots.AntiseratoEoMPep4and
EoMPep 6 (C-terminal motif), however, both showed cross-
reactivitytodistinct,andlargerSVMPmolecularmassvariants
that are likely to be multimeric SVMPs (Figure 5C–5F). While
the function of the EoMPep 3a, 3b, and 6 domains remains
unresolved, their extraordinary cross-generic conservation
suggests biological signiﬁcance. Structurally, the few multi-
meric SVMPs reported to date—the homodimeric PIII SVMPs
VAP1 and HV1 [20,21] and the heterodimeric PIII (PIV) with
an additional disulphide C-type lectin domain [22,23,47]—all
contain an additional cysteine residue. As a result, it has been
implied that the additional cysteine residue facilitates multi-
merization [10,11]. With the exception of EOC0001, however,
which contains an additional Cys-367 (Figure S1) in common
with VAP1 and HV1 [20,21] and consequently may exist as a
native dimer, the majority of ECD motif-containing PIII
SVMPs contain a cysteine ratio of 6:16:12 (metalloproteinase,
Figure 5. Prediction and Experimental Verification of the Immunological Conservation of EoMPep 1–6 in Phylogenetically Distinct African Viper Species
(A and B) The immunological conservation of EoMPep 1–6 is predicted using radar charts comparing the percentage highest bit score results generated
by BLAST searches of EoMPep 1–6 against the E. ocellatus venom gland EST database (VgDbEST) (taken as 100%) with BLAST searches against VgDbEST
databases from (A) C. cerastes (SCW, unpublished data, 2006) and (B) the latter and B. gabonica [35].
(C–F) Experimental assessment of immunological cross-reactivity using pooled sera raised against EoMPep 1–6 as individual MAPs (indicated as
numerals 1–6 above each blot) and EoSVMP string (Str) following nonreduced immunoblotting of whole venom of four viper species (indicated below
each blot). Molecular mass markers are shown to the left. Veh, pVaxSec DNA vehicle control.
DOI: 10.1371/journal.pmed.0030184.g005
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sistent with monomeric, nonprocessed SVMPs [10,13]. These
data suggest that an additional cysteine residue is not
necessarily required for assembly of multimeric SVMPs that
may occur via isomerization of existing disulphides.
EoSVMP String Antiserum Substantially Inhibits Venom-
Induced Hemorrhage In Vivo
The comparative venom hemorrhage-neutralizing efﬁcacy
of antibodies raised by DNA immunization was assessed using
a preclinical minimum hemorrhagic dose assay [4], measured
Figure 6. Neutralization of Venom-Induced Hemorrhage
(A and B) Representative hemorrhagic lesions in the skin of mice injected with one minimum hemorrhagic dose of E. ocellatus venom (A) and C. cerastes
venom (B) following preincubation with PBS, rabbit anti-E. ocellatus venom (anti-EoV), or pooled sera from mice immunized with the indicated DNA
immunogens.
(C and D) The above data expressed as mean standardized area of hemorrhage on the inner surface of the skin (6 1 standard error of the mean). Values
are expressed mean percentage hemorrhage relative to control, pVaxSec (DNA immunogens), or PBS (protein immunogens) which was taken as 100%.
A result statistically significant relative to controls is denoted by an asterisk.
DOI: 10.1371/journal.pmed.0030184.g006
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sera raised by conventional (whole venom) immunization
protocols using rabbit anti-E. ocellatus venom. Antisera against
the EOC00024 MP domain was ineffective at neutralizing E.
ocellatus venom-induced hemorrhage (Figure 6A), and
EOC00024 DC and MPDC antisera apparently offered
limited, but statistically nonsigniﬁcant, protection against E.
ocellatus venom-induced hemorrhage. In comparison, the
EoSVMP string antiserum resulted in a 75% (p ¼ 0.04)
reduction in the mean area of hemorrhage induced by E.
ocellatus venom (Figure 6A and 6C) relative to the DNA
immunization control, pVaxSec. This reduction compared
favorably with that effected by the rabbit anti-E. ocellatus
venom (60%) (p ¼ 0.08), relative to PBS control.
Bioinformatic analysis (Figure 5A) implying that the SVMP
string antiserum would also neutralize the hemorrhagic
activity of C. cerastes venom was experimentally conﬁrmed.
Thus, the EoSVMP string antiserum neutralized the in vivo
hemorrhagic activity of C. cerastes venom by 43% (Figure 6B
and 6D) compared to rabbit anti-E. ocellatus whole venom
(34%) relative to immunization vehicle controls, although
below the level of statistical signiﬁcance.
An almost complete reduction in the intensity, rather
than just the size, of the hemorrhagic lesions induced by
EoSVMP string antiserum is also noteworthy (Figure 6A and
6B), because this is not reﬂected in the statistical compar-
isons of lesion size (Figure 6C and 6D). Reduction in the
intensity of lesions with pVaxSec (DNA control) relative to
positive control (PBS preincubated) venom was expected
and reﬂects baseline inhibition of some PIII SVMPs by
endogenous natural substances in mouse sera such as a2-
macroglobulin [48]; this is unrelated to speciﬁc immunoglo-
bulin activity.
Discussion
Using a bioinformatic approach, we constructed a multi-
epitope DNA immunogen that generated antibody responses
that neutralized venom hemorrhagic toxins, despite the
extensive intraspeciﬁc diversity of viper venom hemorrha-
gins. This epitope-directed approach to the design of
antivenoms is a considerable advance over current (whole
venom) immunization protocols and is a logical progression
from our previous studies using the disintegrin-like domain
of a single SVMP as an immunogen [6].
The precise mechanisms of venom-induced hemorrhage
are not completely understood. Individually characterized
PIII SVMPs from different species have been shown to be
responsible for many of the diverse tissue-disruptive, coagu-
lopathic, and haemostasis-disruptive mechanisms that con-
tribute to hemorrhagic patholo g y( e x t e n s i v e l yr e v i e w e d
recently in [12,14,16–18]). Here we provide evidence impli-
cating a multiplicity of SVMPs in the hemorrhagic pathology
of E. ocellatus envenoming that exceeds estimates of other
viper species reported to date [35,36,40]. The diverse
functions effected by E. ocellatus SVMPs is illustrated by the
sequence similarity (including disulphide-bonded architec-
ture) of (i) the PIII EOC00404 to the prothrombin activator
ecarin [49,50], and of (ii) the PII SVMP EOC00006 to the
ﬁbrinolytic metalloproteinase lebetase [10,51], puriﬁed from
venom that lacks a disintegrin domain [52]. Furthermore, the
disintegrin domain of EOC00006 is also identical to the
platelet aggregation-inhibiting disintegrin ocellatusin [43].
This suggests that the mature EOC00006 is a proteolytically
cleaved precursor of ocellatusin and a metalloproteinase with
ﬁbrinolytic activities. Most notable is the abundance and
diversity of PIII SVMPs containing the ECD motif. This motif
in jararhagin (an SVMP of Bothrops jararaca venom) has been
shown to inhibit collagen-induced platelet aggregation via
a2b1 [45]. The SECD motif has also been shown to be
important in ADAM-1 and 2-mediated sperm-egg interac-
tions [53,54]. Further variations are introduced in the
homologous PIII transcripts, EOC00024 and EOC00022, in
which the SECD domain is substituted for DDCD. Whilst the
ligand speciﬁcity of each of these peptides requires exper-
imental veriﬁcation, taken together these data indicate that
multiple mechanisms are synergistically deployed to achieve
hemorrhagic and systemic bleeding, and therefore a compre-
hensive strategy of toxin epitope-targeted inhibition is
required to develop an effective antivenom.
In light of this diversiﬁcation, generating toxin-neutralising
antisera by using strings of epitopes has not previously been
attempted. This, in part, is due to the assumption that
monospeciﬁc immunotherapeutic antibody responses are
unlikely to be clinically effective against such diverse venom
toxins, and partly because a system to identify epitopes in
large databases has not previously been developed. The
development of robust algorithms to predict the function of
individual, uncharacterized toxin transcripts (especially PIII
SVMPs) has indeed proved difﬁcult [55,56], and because of
the multimeric nature of many venom toxins we approached
the problem of designing toxin-neutralizing immunotherapy
by developing a multi-isoform transcriptomic (i.e., based on
ESTs) approach. We designed and evaluated a systematic
approach to select immunoprotective sequences that provide
the maximal immunological cross-reactivity and toxin-neu-
tralizing efﬁcacy to the majority of isoforms in a multi-
isoform dataset. Importantly, the approach described here
circumvents the absolute requirement for prior structural
and functional information compared to the majority of
existing approaches [57], which typically search for T or B cell
epitopes [58] or preexisting motifs (such as those from
secretory or membrane associated proteins) [59–61], or which
require other prior experimental evidence such as data
derived from expression library immunization screening
protocols [62]. The novelty of this epitope selection approach
lies in the direct use of multiepitope expression bias inherent
in non-normalised EST databases to score epitopes and
inform the design of DNA immunogens that are ‘‘epitopically
balanced’’ by library representation. This is achieved princi-
pally by constraining the consensus residues of antigenic
domains (for example MP-4 TXCRXXRXECDL) to provide a
scaffold upon which degenerate positions (X) are mutated in
silico until the highest-scoring immunogenic peptide is
identiﬁed. By incorporating an analogous frequency matrix
that considers antigenic mutation/variation within a geo-
graphical region, this principle could also be applied to
reﬁning the peptide composition of subunit vaccine candi-
dates to produce those with broader geographical speciﬁcity.
Antiserum raised against the engineered EoSVMP string
DNA immunogen, in accordance with bioinformatic predic-
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venoms of two vipers, E. ocellatus and C. cerastes, which have
markedly distinct distributions (North and West Africa) and
habitats [37,63]. The venom neutralization achieved by the
EoSVMP string antiserum compared favorably with that of
antiserum raised in rabbits by conventional (whole venom)
immunization protocols, despite its lower titre and intensity
on native Western blots. This indicates that the titre of a
toxin-speciﬁc antibody is not necessarily a measure of its
toxin-neutralising efﬁcacy. Whilst lower titres presumably
reﬂect the incorporation of a smaller number of epitopes
into the immunogen, the toxin-neutralising efﬁcacy of the
EoSVMP string antiserum suggests that these selected
epitopes are (i) of functional signiﬁcance and (ii) generate
antibody to native venom toxins.
The cross-generic neutralization observed in this study
may result from the broad modality of functional inhibition
designed into the DNA immunogen, rather than from
mechanistic similarities of hemorrhage between these two
vipers. Comparative Western blots between the EoSVMP
string and antisera raised against individual epitopes as
MAPs demonstrate that the diverse antigen reactivity proﬁle
of EoSVMP string antisera is contributed by EoMPep 1, 3a,
3b, 4, and 6, and that EoSVMP string also recognises
EoMPep 2 and EoMPep 5 MAPs on dot immunoblots
(unpublished data). The immunoreactivity of EoSVMP string
antisera therefore contains contributions from antibodies
speciﬁc to all seven epitopes, indicating the correct
processing and antigen presentation of each constituent
epitope of the EoSVMP string. In comparison, antibodies to
the DC domain of EOC00024 did not markedly neutralize E.
ocellatus venom-induced hemorrhage, despite being of higher
titre and the success of a similar approach using the DC
domain of jararhagin, that neutralized over 70% of B.
jararaca venom-induced hemorrhagic activity [6]. These data
indicate that inhibition of venom-induced hemorrhage is
not simple and that many antibodies are not clinically
beneﬁcial because, despite being of high titre, they fail to
neutralize the functional activity of critically important
SVMP domains.
Our successful use of bioinformatics analysis in selecting
epitopes to create an epitope-string DNA immunogen that
generate antibodies capable of neutralizing the function of a
multi-isomeric group of venom toxins is, to our knowledge,
the ﬁrst demonstration that a single synthetic immunogen
can replicate the toxin-neutralizing capabilities of conven-
tional antivenom. We believe that this new rational basis to
the design of immunotherapy for snake bite can be expanded
to provide a polyspeciﬁc antivenom for disparate venomous
snakes localized within a deﬁned geographical region. We are,
therefore, currently creating epitope-string DNA immuno-
gens to generate antibodies designed to neutralize the
function of SVMPs, phospholipases A2 [64,65], serine pro-
teases [19], C-type lectins [66,67], and disintegrins present in
the venom gland transcriptomes of E. ocellatus [68], B. arietans,
and C. c. cerastes, the vipers responsible for most deaths by
snake bite in Africa. We believe that such an antivenom,
because of its exquisite toxin speciﬁcity, will have improved
toxin-neutralizing IgG titres and therefore pose less risk of
anaphylactoid and serum sickness adverse effects than
conventional antivenom.
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Background. Of the 3,000 species of snakes worldwide, about 600 are
poisonous; poisonous snakes are a particular problem in Africa and
Southeast Asia. Because not all victims of snake bites get to hospital,
estimates of illness and death caused are very approximate. However,
one estimate quoted by the World Health Organization is that 2.5 million
snake bites occur each year and 125,000 are fatal. The effects of snake
bites vary, obviously depending on which snake does the biting, but
immediate effects include swelling (around the bite or of other parts of
the body), death of the area around the bite, and blood clotting
problems. Nowadays, snake bite is treated with ‘‘antivenoms,’’ which are
usually made from immunizing horses or sheep with snake venom.
However, these antivenoms contain many different proteins that can
themselves trigger unpleasant reactions in the recipient. One problem
with developing antivenoms is that venoms contain many hundreds of
different proteins, many of which may contribute to the toxic effect.
Why Was This Study Done? Recent scientific discoveries have led to
new ways of finding which parts of an animal’s genetic sequence are
active in any one particular part of the body, and also whether the
proteins produced from these genes are likely to cause illness. A snake’s
venom gland, where the venom is made, can be analysed this way. The
researchers wanted to use this information to develop a more rational
way of designing antivenoms.
What Did the Researchers Do and Find? They studied the venom
glands of the carpet viper (Echis ocellatus), the most medically important
snake in West Africa. They isolated expressed sequence tags (ESTs)
produced by the venom glands. Each EST is a small part of the active part
of a gene. They then focused on one group of genes that make proteins
called snake venom metalloproteinases (SVMPs), which destroy other
proteins, and which cause many of the severe symptoms, such as
bleeding, seen after snake bite. They identified seven parts of these
SVMPs that were likely to be clinically important, and engineered them
into a single string of DNA. This product is known as an immunogen—
that is, it can produce an immune response in an animal. And when this
immunogen was injected into mice, the researchers found that the
serum (the part of the blood that contains antibodies) from these mice
did have a specific effect against the SVMPs in snake venom. It also had
some effect, again in mice, against bleeding caused by small doses of
snake venom.
What Do These Findings Mean? These results suggest that it is possible
to use some of the newest genetic techniques to design immunogens
that can be used to make highly specific, toxin-neutralizing antisera.
These immunogens are a possible improvement over conventional
antivenoms that are raised against whole venom. This approach could
mean that lower doses of antivenoms would be needed than for
conventional antivenoms. In addition, it may also be possible to design
antivenoms that work against different species of snake venom. Results
such as this may persuade a company that it is worth investing further in
such antivenoms; as with many diseases of the poorer parts of the world,
snake bites have not been of great interest to large pharmaceutical
companies. In another paper published in PLoS Medicine, Jose ´ Marı ´a
Gutie ´rrez et al. discuss the global problem of snake bites.
Additional Information Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030184
  World Health Organization page on animal bites, including snakes
  MedlinePlus Medical Encyclopedia pages of health information (these
pages are most relevant in the US)
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